Xeris Biopharma (XERS) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Xeris Biopharma (NASDAQ: XERS):

• 11/7/2026 – Xeris Biopharma was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 11/6/2026 – Xeris Biopharma had its “outperform” rating reaffirmed by Oppenheimer. They now have a $21.00 price target on the stock, up from $18.00.
• 11/6/2026 – Xeris Biopharma had its “neutral” rating reaffirmed by Piper Sandler. They now have a $12.00 price target on the stock, up from $8.00.
• 11/6/2026 – Xeris Biopharma had its price target raised by HC Wainwright from $10.00 to $18.00. They now have a “buy” rating on the stock.
• 10/6/2026 – Xeris Biopharma had its price target raised by Barclays from $12.00 to $14.00. They now have an “overweight” rating on the stock.
• 9/19/2026 – Xeris Biopharma was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/10/2026 – Xeris Biopharma had its price target raised by Leerink Partners from $12.00 to $16.00. They now have an “outperform” rating on the stock.

Xeris Biopharma Stock Up 2.7%

NASDAQ:XERS traded up $0.41 during trading hours on Monday, hitting $15.61. 2,488,567 shares of the company traded hands, compared to its average volume of 2,107,818. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The company has a market cap of $2.85 billion, a PE ratio of -312.12 and a beta of 0.61. The firm’s 50-day simple moving average is $9.62 and its 200-day simple moving average is $7.62. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $15.70.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The business had revenue of $107.23 million for the quarter, compared to analysts’ expectations of $101.68 million. Xeris Biopharma had a negative net margin of 1.76% and a positive return on equity of 429.43%. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Insider Buying and Selling

In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $51,150.00. Following the transaction, the insider owned 1,346,053 shares of the company’s stock, valued at approximately $13,770,122.19. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $12.49, for a total value of $312,250.00. Following the completion of the transaction, the insider owned 1,559,208 shares of the company’s stock, valued at $19,474,507.92. This trade represents a 1.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 173,332 shares of company stock worth $1,721,471. 4.35% of the stock is owned by company insiders.

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.